Business
Nanox Announces Fourth Quarter of 2024 Financial Results and Provides Business Updates
Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EU Advanced commercialization globally, signing new customer and channel partner agreements for Nanox.ARC and Nanox AI Management to host conference call and webcast Monday, March 31, 2025 at 8:30 AM ET PETACH TIKVA, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for th
About this update from Nano-x Imaging Ltd
[{"type":"image","alt":"Nano-X Imaging LTD.","displaySize":"","headline":null,"caption":"Nano-X Imaging LTD.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/bb68e1b6e7ee0b6ba64825d135e6c05a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/13ZFHOV0PmhW0sUP.nWsmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bb68e1b6e7ee0b6ba64825d135e6c05a","width":250,"height":64}},"lazy":false},{"type":"text","content":"Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EU","length":100,"tagName":"p"},{"type":"text","content":"Advanced commercialization globally, signing new customer and channel partner agreements for Nanox.ARC and Nanox AI","length":115,"tagName":"p"},{"type":"text","content":"Management to host conference call and webcast Monday, March 31, 2025 at 8:30 AM ET","length":83,"tagName":"p"},{"type":"text","content":"PETACH TIKVA, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2024, and provided a business update.","length":272,"tagName":"p"},{"type":"text","content":"Recent Highlights:","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated $3.0 million in revenue in the fourth quarter of 2024, compared to $2.4 million in the fourth quarter of 2023.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory achievements: FDA clearance of the Nanox.ARC for general use in December 2024, and a CE mark of the Nanox.ARC in February 2025 with no adjunctive requirements. The Company also submitted the Nanox.ARC X for 510 (k) FDA clearance.","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"US commercialization advanced with a new Nanox.ARC channel partner agreement.","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"During the first quarter of 2025, we signed two new Nanox.AI customers, Ezra AI Inc., a healthcare AI company revolutionizing consumers’ screening for early cancer detection, and another outpatient medical imaging provider.","length":228,"tagName":"p"}]},{"val":[{"type":"text","content":"Recently&nb...